The pitch borders on science fiction. Inject water and nutrients into depleted oil wells across Texas or California. Let native bacteria—microbes that have survived down there for millennia—chew through the leftover hydrocarbons. Then harvest the hydrogen they burp out.
Houston-based Eclipse Energy, a startup that rebranded from the cheerier-sounding Gold H2, insists this isn't fantasy. The company claims in its materials that its biological approach could produce hydrogen at around $0.50 per kilogram, though this figure hasn't been independently verified. If that holds, it would be a fraction of what electrolytic methods cost today—and potentially a game-changer in the stubborn economics of clean hydrogen.
Last June, Eclipse ran what it described as a first-of-its-kind field demonstration in California's San Joaquin Basin. The result: hydrogen concentrations hitting 40% in the gas stream pulled from the well. Not definitive proof of commercial viability, but enough to catch eyes beyond the usual cleantech evangelists.
By December, Weatherford International—the publicly traded oilfield services behemoth—had signed on as both strategic partner and investor. The amount of Weatherford's capital investment remains undisclosed, but projects were slated to kick off this January. For a startup still proving out its technology, landing Weatherford brought more than capital. It brought subsurface expertise and global field execution muscle, the kind of operational heft that can mean the difference between lab curiosity and something scalable.
"This collaboration accelerates our path to commercial deployment," CEO Prabhdeep Singh Sekhon said at the time. Perhaps more than he expected—four months later, in April, Eclipse inked a memorandum of understanding with Wood, the engineering firm now owned by Sidara. Wood would serve as the preferred engineering partner for global commercialization, with plans to publish levelized cost and carbon intensity data sometime in the first half of this year.
That report hasn't surfaced publicly yet, at least not as of mid-June.
Threading the Needle Between Oil and Clean Energy
Eclipse is playing a delicate game. It positions itself as a clean energy innovator while leaning hard on the infrastructure, know-how, and checkbooks of Big Oil. ChampionX, another oilfield services player, supported the California trial. The partnerships read like a roster of companies that have drilled, measured, and monetized hydrocarbons for decades.
The approach itself sits in a strange middle ground. It's not quite natural geologic hydrogen—the kind that accumulates on its own in underground reservoirs, waiting to be tapped like oil was a century ago. But it's not conventional production either, like steam methane reforming, which dominates today's hydrogen market and relies on natural gas.
Instead, Eclipse engineers the process. Nutrients go down. Subsurface microbes metabolize residual oil. Some CO2 stays trapped below; hydrogen rises through existing wellbores. It's stimulated hydrogen production, a category that barely existed a few years ago.
That distinction matters commercially. The U.S. Geological Survey released its first map of prospective natural hydrogen resources in January of last year, but uncertainty remains high about where economically recoverable deposits actually exist. Eclipse's model, in theory, turns known depleted oil fields—tens of thousands scattered across the U.S.—into candidate sites. The infrastructure is already there. The wells are already drilled.
The $0.50 Question
The cost claim is where Eclipse's narrative gets interesting, and where skepticism is warranted. Half a dollar per kilogram would undercut nearly every other hydrogen pathway by a wide margin.
For context: the Department of Energy's 2024 Liftoff report, published last year, pegged electrolytic hydrogen costs at $5 to $7 per kilogram, before accounting for delivery or tax credits. Steam methane reforming, the incumbent technology, typically runs $1 to $2 per kilogram before carbon capture gets added to the equation.
Eclipse hasn't published an independent techno-economic analysis. The $0.50 figure remains a company target, not a verified benchmark. And there's a long road between achieving 40% hydrogen concentration in a single well and building a scalable, economically viable production system.
But if the microbes deliver, the implications would ripple beyond hydrogen markets.
A Suddenly Crowded Field

Eclipse isn't the only player chasing geologic hydrogen, and the competition is moving fast.
Koloma, a natural hydrogen explorer, has raised over $300 million across multiple rounds through last year. HyTerra and Prometheus Hydrogen announced plans in February to deliver purified natural hydrogen by December of this year—an aggressive timeline, to put it mildly. The U.S. Air Force, through its Chimaera Fund, launched a geologic hydrogen energy resilience initiative this spring, selecting initial partners including HyTerra and Helix Exploration.
In May, GeoRedox and Canada Nickel said they'd develop a stimulated geologic hydrogen well in Ontario. Vema Hydrogen, profiled by TechCrunch earlier this year, is pursuing what it calls "engineered mineral hydrogen."
The window for early commercial demonstrations appears to be now—2026 and into 2027. Eclipse's June trial gave it an early mover narrative, but first doesn't always mean best. Plenty of clean energy technologies have stumbled between pilot and commercial scale.
What Comes Next

Eclipse spun out of Cemvita in September 2022 with backing from Chart Industries and 8090 Industries. Funding amounts weren't disclosed, a common refrain in this story. Sekhon, who took over as CEO in May 2024, came from stints at NextEra Energy Resources and Hess—companies that know how to build and operate energy infrastructure at scale.
The company maintains offices in Houston and has positioned its technology toward potential offtakers like data centers, which are increasingly desperate for low-carbon power sources to offset their ballooning electricity consumption. An October partnership with Armada focused on commercializing edge technologies for off-grid applications.
Whether Eclipse's microbes can actually deliver hydrogen at $0.50 per kilogram at commercial scale remains unproven. The field trial was encouraging. The partnerships with Weatherford and Wood signal serious intent. But the hydrogen industry is littered with promising technologies that couldn't scale, couldn't pencil out economically, or both.
Eclipse has the pieces in place to find out. The question is whether the bacteria can do what the spreadsheets say they can.
